|
Nr. |
Eintrag |
|
1 |
Jamshed, Shazia Qasim et al.:
Is bioethics in pharmacy inconceivable?
In: Journal of the Pakistan Medical Association, 2011, Vol. 61 (4), 407-408 [Online]. Accessed:http://www.jpma.org.pk/PdfDownload/2718.pdf [2011 June 03] |
|
2 |
Dameh, Majd; Green, James; Norris, Pauline:
Over-the-counter sales of antibiotics from community pharmacies in Abu Dhabi
In: Pharmacy World and Science, 2010, Vol. 32 (5), 643-650 |
|
3 |
Meier, Barry:
Lawsuit challenges marking of stents.
In: New York Times, 2010 (2010-01-15), B3 |
|
4 |
Salcido, Richard:
Qui tam: False Claims Act.
In: Advances in skin & wound care, 2010, Vol. 23 (11), 487 |
|
5 |
Comité Consultatif de Bioéthique (Belgique)
= Belgian Advisory Committee on Bioethics:
Avis n° 47 du 9 mars 2009 relatif aux implications éthiques de la législation concernant les programmes d'usage compassionnel (compassionate use) et les programmes médicaux d'urgence (medical need) L'usage «off label» ou usage hors des indications reconnues. Demande d'avis en date du 27 juin 2007, de Monsieur Marc Bogaert, Président du comité d'éthique médicale de l'AZ Sint-Lucas à Gand. [Opinion no. 47 of 9 March 2009 on the ethical implications of legislation on compassionate use and medical need programs. Unregistered and off-label usage]
In: Bioethica Belgica, 2009, 33, 45-56 |
|
6 |
Epstein, Richard A.:
Cancer patients deserve faster access to life-saving drugs [opinion]
In: Wall Street Journal, 2009 (2009-05-02), A11 |
|
7 |
Meier, Barry:
Life, death and liability: An effort to restore the right to sue device makers
In: New York Times, 2009 (2009-02-20), B1, B4 |
|
8 |
Tanne, Janice Hopkins:
FDA lets drug firms distribute articles about off-label uses [news]
In: BMJ: British Medical Journal, 2009, Vol. 338 (7688), 193 |
|
9 |
A win for injured patients [editorial]
In: New York Times, 2009 (2009-03-05), A30 |
|
10 |
Drugs v. devices [editorial]
In: New York Times, 2009 (2009-03-15), WK11 |
|
11 |
Anderson, Geoffrey M.; Juurlink, David; Detsky, Allan S.:
Newly approved does not always mean new and improved [commentary]
In: JAMA: The Journal of the American Medical Association, 2008, Vol. 299 (13), 1598-1600 |
|
12 |
Curfman, Gregory D.; Morrissey, Stephen; Drazen, Jeffrey M.:
Why doctors should worry about preemption
In: New England Journal of Medicine, 2008, Vol. 359 (1), 1-3 |
|
13 |
Dudzinski, David M.; Kesselheim, Aaron S.:
Scientific and legal viability of follow-on protein drugs
In: New England Journal of Medicine, 2008, Vol. 358 (8), 843-849 |
|
14 |
Giles, Jim:
Hard to swallow
In: New Scientist, 2008, Vol. 197 (2640), 37-39 |
|
15 |
Greenhouse, Linda:
Justices shield medical devices from lawsuits; a White House victory; ruling holds approval by FDA overrides some state cases
In: New York Times, 2008 (2008-02-21), A1, A18 |
|
16 |
Liptak, Adam:
Drug label, maimed patient and crucial test for justices
In: New York Times, 2008 (2008-09-19), A1, A12 |
|
17 |
Stafford, Randall S.:
Regulating off-label drug use -- rethinking the role of the FDA
In: New England Journal of Medicine, 2008, Vol. 358 (14), 1427-1429 |
|
18 |
Charatan, Fred:
US drug company to pay $5bn in rofecoxib claims [news]
In: BMJ:British Medical Journal, 2007, Vol. 335 (7628), 1011 |
|
19 |
Croskerry, Pat G.:
Prescribing powers for pharmacists [letter]
In: CMAJ/JAMC Canadian Medical Association Journal, 2007, Vol. 176 (1), 67 |
|
20 |
Dresser, Rebecca:
The curious case of off-label use
In: Hastings Center Report, 2007, Vol. 37 (3), 9-11 |
